These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17168450)

  • 41. [Erlotinib in the treatment of non-small cell lung cancer].
    Ostoros G; Döme B
    Magy Onkol; 2006; 50(3):237-41. PubMed ID: 17099784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
    Uhm JE; Park BB; Ahn MJ; Lee J; Ahn JS; Kim SW; Kim HT; Lee JS; Kang JH; Cho JY; Song HS; Park SH; Sohn CH; Shin SW; Choi JH; Park K
    J Thorac Oncol; 2009 Sep; 4(9):1136-43. PubMed ID: 19687764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing EGFR mutations.
    Marchetti A; Felicioni L; Buttitta F
    N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
    [No Abstract]   [Full Text] [Related]  

  • 45. Erlotinib in lung cancer.
    Nabhan C; Bitran JD
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erlotinib in non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P; Colantuoni G; Del Gaizo F; Ferrara C; Nicolella D; Guerriero C
    Expert Opin Pharmacother; 2007 Oct; 8(15):2579-92. PubMed ID: 17931092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
    Yang X; Yang K; Kuang K
    Curr Oncol Rep; 2014 Jun; 16(6):390. PubMed ID: 24807015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Updated data from the Iressa survival in lung cancer trial.
    Tyagi P
    Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
    [No Abstract]   [Full Text] [Related]  

  • 51. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic profiling identifies lung tumor responsiveness to erlotinib.
    Fan TW; Lane AN; Higashi RM; Bousamra M; Kloecker G; Miller DM
    Exp Mol Pathol; 2009 Aug; 87(1):83-6. PubMed ID: 19409891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
    Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
    J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
    Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA
    J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
    Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
    Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.